NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that
RNS Number : 2460R Renalytix AI PLC 04 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights New York , 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance
RNS Number : 8363Q Renalytix AI PLC 02 March 2021 RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 NEW YORK , March 2, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics
RNS Number : 8349Q Renalytix AI PLC 02 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Half-year Report Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on
Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease NEW YORK and SALT LAKE CITY, Feb.
RNS Number : 1616Q Renalytix AI PLC 24 February 2021 This announcement contains inside information Renalytix AI plc (" RenalytixAI " or the " Company ") The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health Innovative partnership to enable health system-wide
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance
RNS Number : 9649P Renalytix AI PLC 23 February 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") RenalytixAI to announce Financial Results for six and three months ended December 31, 2020 NEW YORK , February 23, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), the
Event Featuring Leading Clinicians, Biotech Innovators and Federal Health Agencies to Highlight Innovation and Opportunity in Kidney Health NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company,
